Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") announced it
has initated a clinical and manufacturing collaboration with
Celularity, Inc., a Warren, New Jersey, based clinical-stage cell
therapeutics company delivering transformative allogeneic cellular
therapies derived from the postpartum human placenta. The objective
of the collaboration is to expand the therapeutic use of
Celularity's CYNK-001, an allogeneic, off-the-shelf,
placental-derived Natural Killer (NK) cell therapy, to the
treatment and prevention of coronavirus infections.
NK cells are the foundation of the natural
innate immune response. NK cells derived from the placenta are well
tolerated, intrinsically safe and versatile, allowing potential
uses across a range of organs and tissues. NK cell therapy is
currently being investigated as a treatment for various liquid and
solid tumors, but also has the demonstrated potential to be
effective against virally infected cells.
Under the contemplated collaboration, Sorrento
and Celularity would assess CYNK-001 as a potential novel therapy
for the treatment and prevention of coronaviruses, focusing in
particular on the newly emerged 2019 Novel Coronavirus (2019-nCoV).
In addition, Sorrento would utilize current existing capacity in
its “state-of-the-art” cGMP cell therapy manufacturing facilities
in San Diego, California, to supplement Celularity's new cGMP
facility in Florham Park, New Jersey. The combined capacity would
support the rapid scale-up and sustained production of the novel
cell therapy.
Sorrento is already in contact with leading
scientists and local Chinese experts to discuss the clinical
validation and logistics requirements to fast-track CYNK-001 cell
therapy available in China for this particularly urgent
indication.
Sorrento owns 25% of Celularity and the
companies have a longstanding relationship. Both companies have
expressed their interest in starting clinical development efforts
for anti-coronavirus allogeneic NK cell therapy immediately.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric,
biopharmaceutical company developing new therapies to turn
malignant cancers into manageable and possibly curable diseases.
Sorrento's multimodal multipronged approach to fighting cancer is
made possible by its’ extensive immuno-oncology platforms,
including key assets such as fully human antibodies (“G-MAB™
library”), clinical stage immuno-cellular therapies (“CAR-T”),
intracellular targeting antibodies (“iTAbs”), antibody-drug
conjugates (“ADC”), and clinical stage oncolytic virus
(“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for patients
is also demonstrated by our effort to advance a first-in-class
(TRPV1 agonist) non-opioid pain management small molecule,
resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system)
1.8% for the treatment of post-herpetic neuralgia. Resiniferatoxin
is completing a phase IB trial in terminal cancer patients and a
phase 1B trial in osteoarthritis patients. ZTlido® was approved by
the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com
Forward-Looking Statements
This press release and any statements made for and during any
presentation or meeting contain forward-looking statements related
to Sorrento Therapeutics, Inc., under the safe harbor provisions of
Section 21E of the Private Securities Litigation Reform Act of 1995
and subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include statements regarding the expected timing for the
formation of the collaboration, initiation and completion of
ongoing studies for coronavirus using NK cells and data read-outs
related thereto; the expected timing for commencing and completing
registrational studies, and for submitting a NDA application for NK
cells for the treatment and/or prevention for coronavirus; the
likely doses for any upcoming pivotal studies; any potential market
for NK cells for the treatment and prevention of coronavirus and
Sorrento’s potential position in the anti-viral immunity industry.
Risks and uncertainties that could cause our actual results to
differ materially and adversely from those expressed in our
forward-looking statements, include, but are not limited to: risks
related to Sorrento's and its subsidiaries', affiliates’ and
partners’ technologies and prospects and collaborations with
partners, including, but not limited to, potential collaboration
with Celularity, using NK cells for the treatment and prevention of
coronavirus infections; risks related to seeking regulatory
approvals and conducting and results of clinical trials; the
clinical and commercial success of the treatment and prevention of
coronavirus infections using NK cells; the viability and success of
using NK cells for treatments in anti-viral therapeutic areas,
including coronavirus; clinical development risks, including risks
in the progress, timing, cost, and results of clinical trials and
product development programs; risk of difficulties or delays in
obtaining regulatory approvals; risks that clinical study results
may not meet any or all endpoints of a clinical study and that any
data generated from such studies may not support a regulatory
submission or approval; risks related to seeking regulatory
approvals and conducting clinical trials; risks of supplying drug
product; risks related to leveraging the expertise of its
employees, subsidiaries, affiliates and partners to assist the
company in the execution of its strategies; risks related to
Sorrento’s debt obligations and other risks that are described in
Sorrento's most recent periodic reports filed with the Securities
and Exchange Commission, including Sorrento's Annual Report on Form
10-K for the year ended December 31, 2018, and subsequent Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission, including the risk factors set forth in those filings.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release and we undertake no obligation to update any
forward-looking statement in this press release except as required
by law.
Media and Investor Relations
Contact: Alexis Nahama, DVM (SVP Corporate Development)
Telephone: 1.858.203.4120
Email: mediarelations@sorrentotherapeutics.com
About Celularity
Celularity, headquartered in Warren, N.J., is a
clinical-stage cell therapeutics company delivering transformative
allogeneic cellular therapies derived from the postpartum human
placenta. Using proprietary technology in combination with its
IMPACT™ platform, Celularity is the only company harnessing the
purity and versatility of placental-derived cells to develop and
manufacture innovative and highly scalable off-the-shelf treatments
for patients with cancer, inflammatory and age-related diseases. To
learn more, please visit www.celularity.com.
Media and Investor Relations
Contact: John R. Haines (EVP & Chief Administrative
Officer)
Email: john.haines@celularity.com
Sorrento® and the Sorrento logo are registered trademarks of
Sorrento Therapeutics, Inc.ZTlido® and G-MAB™ are trademarks owned
by Scilex Pharmaceuticals Inc. and Sorrento,
respectively.Seprehvir®, is a registered trademark of
Virttu Biologics Limited, a wholly-owned subsidiary of TNK
Therapeutics, Inc. and part of the group of companies owned by
Sorrento Therapeutics, Inc.All other trademarks are the property of
their respective owners. © 2020 Sorrento Therapeutics, Inc. All
Rights Reserved.
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Apr 2023 to Apr 2024